See Today's Golden Star Stocks 🔥 Free for 7 Days See Today's Golden Star Stocks 🔥 Free for 7 Days
NASDAQ:RIGL

Rigel Pharmaceuticals Stock Predictions

etoro logo Buy RIGL
*Your capital is at risk
$35.61
-0.120 (-0.336%)
At Close: Jun 23, 2026
Forecast Earnings Financials Insider Trading Signals Historical Prices Predictions News Profile
Currently predicting for Wed, 24 Jun 2026
RIGL Live board
Community Bull/Bear
Target Next close

Join the RIGL prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

RIGL Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in
Forecast Desk

3-Month Forecasts For RIGL

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

RIGL Predictions History

Predictor Target Session Target Price Accuracy
Community predictor Next session USD target Record locked
Ranked predictor Previous session Bullish/Bearish Score locked

See the prediction record

Register to view community history, predictor profiles, accuracy, scores, and your own prediction trail for RIGL.

Create free account Log in
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Log in or create a free account to view and request 66-session forecasts for RIGL.
  • Price path
  • Approved predictor
  • 3-month horizon
Create Free Account Log In To View Forecasts
ABOUT RIGEL PHARMACEUTICALS
Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical t...
Read Full Profile Here
GOLDEN STAR
Ticker Change Signal Date
IDYA
$28.98
20.46% Jun 12
DHI
$146.71
6.39% Jun 10
E
ETD
$20.67
4.79% Jun 05
EAT
$140.46
16.94% Jun 05
OSW
$24.00
17.08% Jun 04
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE